top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACELYRIN, INC. - Common Stock (NQ:SLRN)

2.270 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACELYRIN, INC. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Earnings Preview: Acelyrin ↗
 
Via Benzinga
News headline image
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024 ↗
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 ↗
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 ↗
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep ↗
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. 
Via Benzinga
News headline image
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session ↗
 
Via Benzinga
News headline image
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. Announces Leadership Transition
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients ↗
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... 
Via Benzinga
News headline image
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page